- After surgery, Merck's (NYSE:MRK) Keytruda (pembrolizumab) can reduce the risk of renal cell carcinoma returning or death by nearly one-third, new data shows.
- Results from the KEYNOTE-564 trial demonstrated that after surgical removal of a kidney or removal of lesions, those on the anti-PD-1 biologic saw a 46% reduction in the risk of death compared to those on placebo.
- Median follow-up was 24.1 months.
- The trial will continue to evaluate overall survival, a secondary endpoint.
- Results will be formally presented on June 6 at the American Society of Clinical Oncology ("ASCO") Annual Meeting.
- #ASCO21
- Merck shares are up 0.3% to $74.10 in after-hours trading.